

Product Data Sheet

Product Name: L-DOPA-d6

Cat. No.: GC71832

Chemical Properties

Cas. No. 713140-75-1

Formula $C_9H_5D_6NO_4$ M.Wt 203.22


Solubility 0.1 M HCL : 20 mg/mL (98.42 mM); ultrasonic and warming and adjust pH to 2 with HCl and heat to 60°C);
H₂O : 1 mg/mL (4.92 mM; Need ultrasonic)

Storage -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

L-DOPA-d6 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

disease[1][2][3].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

References:

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019;53(2):211-216.
- [2]. Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. *Clin Chem*. 1992 Dec;38(12):2405-10.
- [3]. Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. *Parkinsonism Relat Disord*. 2008;14(4):273-80. Epub 2007 Nov 7.
- [4]. Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. *Front Aging Neurosci*. 2018 Aug 3;10:237.
- [5]. Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. *Yonsei Med J*. 2013 Mar 1;54(2):330-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA